A5041802063- Immunotherapy and Immune Responses
- vaccines and immunoinformatics approaches
- Viral-associated cancers and disorders
- Soft tissue tumor case studies
- Cutaneous Melanoma Detection and Management
- Advanced biosensing and bioanalysis techniques
- Genetics and Neurodevelopmental Disorders
- Sarcoma Diagnosis and Treatment
- Soft tissue tumors and treatment
- Melanoma and MAPK Pathways
- Studies on Chitinases and Chitosanases
- CAR-T cell therapy research
- Animal Virus Infections Studies
- Cancer Immunotherapy and Biomarkers
- Cancer Genomics and Diagnostics
- Autism Spectrum Disorder Research
- RNA Interference and Gene Delivery
- Extracellular vesicles in disease
- Monoclonal and Polyclonal Antibodies Research
- RNA modifications and cancer
- T-cell and Retrovirus Studies
- Chromatin Remodeling and Cancer
- Neuroblastoma Research and Treatments
- Epigenetics and DNA Methylation
- Virus-based gene therapy research
Massachusetts General Hospital
2017-2025
Harvard University
2011-2025
MGH Institute of Health Professions
2025
Broad Institute
2023-2024
Massachusetts Institute of Technology
2023-2024
Memorial Sloan Kettering Cancer Center
2019-2023
Dana-Farber Cancer Institute
2023
University of Verona
2018
Boston University
2011
Boston Children's Hospital
2006-2008
Abstract Improved biomarkers are needed for early cancer detection, risk stratification, treatment selection, and monitoring response. Although proteins can be useful blood-based biomarkers, many have limited sensitivity or specificity these applications. Long INterspersed Element-1 (LINE-1) open reading frame 1 protein (ORF1p) is a transposable element overexpressed in carcinomas high-risk precursors during carcinogenesis with negligible expression normal tissues, suggesting ORF1p could...
Plasma-derived extracellular vesicles potentially enable prediction and tracking of immunotherapy response.
The methyl-DNA binding protein MeCP2 is emerging as an important regulator of drug reinforcement processes. Psychostimulants induce phosphorylation at Ser421; however, the functional significance this posttranslational modification for addictive-like behaviors was unknown. Here we show that Ser421Ala knock-in mice display both a reduced threshold induction locomotor sensitization by investigator-administered amphetamine and enhanced behavioral sensitivity to reinforcing properties...
Although tricyclic antidepressants rapidly activate monoaminergic neurotransmission, these drugs must be administered chronically to alleviate symptoms of depression. This observation suggests that molecular mechanisms downstream monoamine receptor activation, which include the induction gene transcription, underlie chronic antidepressant-induced changes in behavior. Here we show methyl-CpG-binding protein 2 (MeCP2) regulates behavioral responses antidepressant treatment. Imipramine...
Checkpoint inhibitors have revolutionized cancer treatment, but a significant proportion of patients do not respond to these therapies, underscoring the need for alternative strategies. Although gene therapy has made substantial strides, its application in solid tumors remains underexplored, with limited treatments approved. Here, we further investigated approach non-replicating adenoviral vectors encoding alternate reading frame (ARF) and interferon beta (IFNb) tested it clinically relevant...
Abstract Background: Pancreatic ductal adenocarcinoma (PDAC) has a desmoplastic extracellular matrix enriched with collagen type I (COL1) and poor CD8+ tumor-infiltrating lymphocyte (TIL) infiltration. CD49b, key receptor, been implicated in PDAC progression, but its role immune exclusion remains unclear. Objective: This study investigates the functional of CD49b modulating anti-tumor responses architecture PDAC, while exploring therapeutic potential against PDAC. Methods: Collagen receptors...
Abstract Clinical decisions for immune checkpoint blockade (ICB) treatment currently rely on tumor-based biomarkers such as mutational burden, microsatellite instability, and PD-L1 expression. While these markers serve valuable proxies tumor antigenicity the status of microenvironment, they fail to account fitness a patient’s T cells, critical factor in anti-tumor immunity. Direct assessment cell functional capacity could complement existing improve patient stratification efficacy prediction...
Many cancer patients treated with immune checkpoint blockade (ICB) do not have durable treatment responses. Circulating biomarkers the potential to identify primary resistance or early progression on therapy alter course and avoid unnecessary toxicity. Unbiased multimodal proteomic profiling in blood has been underexplored due previously limited scalability of multiplexing technologies cohorts lacking time-series sampling. To address this, we performed plasma >2,900 proteins...
Abstract Background Immunotherapy has improved overall survival in metastatic melanoma. Response to therapy can be difficult evaluate as the traditionally used RECIST 1.1 criteria do not capture heterogeneous responses. Here we describe clinical characterization of melanoma patients with a clinically defined mixed response immunotherapy. Methods This was single institution, retrospective analysis stage IV who received first-line anti-CTLA-4, anti-PD1, or combination anti-CTLA-4/anti-PD1....
Abstract Background In the current era of effective adjuvant therapies and de-escalation surgery, distinguishing which patients with high-risk stage II melanoma are at increased risk recurrence after excision primary lesion is essential to determining appropriate treatment surveillance plans. Methods A single-center retrospective study analyzed IIB or IIC melanoma. Demographic tumor data were collected, genomic analysis formalin-fixed, paraffin-embedded tissue samples was performed via an...
Metastatic bone disease is estimated to develop in up 17% of patients with melanoma, compromising skeleton integrity resulting skeletal-related events (SREs), which impair quality life and reduce survival. The objective the study was investigate (1) proportion melanoma developing SREs following diagnosis metastasis (2) predictors for this patient cohort.
ABSTRACT Surgical removal of lymph nodes (LNs) to prevent metastatic recurrence, including sentinel node biopsy (SLNB) and completion dissection (CLND), are performed in routine practice. However, it remains controversial whether removing LNs which critical for adaptive immune responses impairs checkpoint blockade (ICB) efficacy. Here, our retrospective analysis demonstrated that stage III melanoma patients retain robust response anti-PD1 inhibition after CLND. Using orthotopic murine...